Sniper2L is a high-fidelity Cas9 variant with high activity

被引:17
|
作者
Kim, Young-hoon [1 ,2 ,3 ,4 ]
Kim, Nahye [2 ,5 ]
Okafor, Ikenna [6 ]
Choi, Sungchul [2 ]
Min, Seonwoo [7 ]
Lee, Joonsun [1 ]
Bae, Seung-Min [1 ]
Choi, Keunwoo [1 ]
Choi, Janice [8 ]
Harihar, Vinayak [8 ]
Kim, Youngho [1 ]
Kim, Jin-Soo [9 ,10 ]
Kleinstiver, Benjamin P. [11 ,12 ,13 ]
Lee, Jungjoon K. [1 ]
Ha, Taekjip [8 ,14 ,15 ,16 ]
Kim, Hyongbum Henry [2 ,4 ,5 ,17 ,18 ,19 ,20 ]
机构
[1] Toolgen, Seoul, South Korea
[2] Yonsei Univ, Dept Pharmacol, Coll Med, Seoul, South Korea
[3] Yonsei Univ, Grad Program Biomed Engn, Coll Med, Seoul, South Korea
[4] Yonsei Univ, Grad Program Nanosci & Technol, Seoul, South Korea
[5] Yonsei Univ, Grad Sch Med Sci, Brain Korea Project 21, Coll Med, Seoul, South Korea
[6] Johns Hopkins Univ, Dept Biol, Baltimore, MD USA
[7] LG AI Res, Seoul, South Korea
[8] Johns Hopkins Univ, Dept Biophys, Baltimore, MD 21218 USA
[9] Natl Univ Singapore, Dept Biochem, Singapore, Singapore
[10] Natl Univ Singapore, NUS Synthet Biol Clin & Technol Innovat SynCTI, Singapore, Singapore
[11] Massachusetts Gen Hosp, Ctr Genom Med, Boston, MA USA
[12] Massachusetts Gen Hosp, Dept Pathol, Boston, MA USA
[13] Harvard Med Sch, Dept Pathol, Boston, MA USA
[14] Johns Hopkins Univ, Dept Biophys & Biophys Chem, Baltimore, MD 21218 USA
[15] Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21218 USA
[16] Howard Hughes Med Inst, Baltimore, MD 21250 USA
[17] Inst for Basic Sci Korea, Ctr Nanomed, Seoul, South Korea
[18] Yonsei Univ, Yonsei Inst Basic Sci Inst, Seoul, South Korea
[19] Yonsei Univ, Severance Biomed Sci Inst, Coll Med, Seoul, South Korea
[20] Yonsei Univ, Inst Immunol & Immunol Dis, Coll Med, Seoul, South Korea
基金
美国国家卫生研究院; 新加坡国家研究基金会;
关键词
TARGET CLEAVAGE; DNA; RNA; CRISPR; SPECIFICITY; NUCLEASES; COMPLEX;
D O I
10.1038/s41589-023-01279-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Although several high-fidelity SpCas9 variants have been reported, it has been observed that this increased specificity is associated with reduced on-target activity, limiting the applications of the high-fidelity variants when efficient genome editing is required. Here, we developed an improved version of Sniper-Cas9, Sniper2L, which represents an exception to this trade-off trend as it showed higher specificity with retained high activity. We evaluated Sniper2L activities at a large number of target sequences and developed DeepSniper, a deep learning model that can predict the activity of Sniper2L. We also confirmed that Sniper2L can induce highly efficient and specific editing at a large number of target sequences when it is delivered as a ribonucleoprotein complex. Mechanically, the high specificity of Sniper2L originates from its superior ability to avoid unwinding a target DNA containing even a single mismatch. We envision that Sniper2L will be useful when efficient and specific genome editing is required.
引用
收藏
页码:972 / +
页数:31
相关论文
共 50 条
  • [21] FrCas9 is a CRISPR/Cas9 system with high editing efficiency and fidelity
    Zifeng Cui
    Rui Tian
    Zhaoyue Huang
    Zhuang Jin
    Lifang Li
    Jiashuo Liu
    Zheying Huang
    Hongxian Xie
    Dan Liu
    Haiyan Mo
    Rong Zhou
    Bin Lang
    Bo Meng
    Haiyan Weng
    Zheng Hu
    Nature Communications, 13
  • [22] FrCas9 is a CRISPR/Cas9 system with high editing efficiency and fidelity
    Cui, Zifeng
    Tian, Rui
    Huang, Zhaoyue
    Jin, Zhuang
    Li, Lifang
    Liu, Jiashuo
    Huang, Zheying
    Xie, Hongxian
    Liu, Dan
    Mo, Haiyan
    Zhou, Rong
    Lang, Bin
    Meng, Bo
    Weng, Haiyan
    Hu, Zheng
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [23] Kinetic Basis for Improved Specificity of CRISPR/Cas9 High Fidelity Variants
    Liu, Mu-Sen
    Gong, Shanzhong
    Yu, Helen-Hong
    Taylor, David W.
    Johnson, Kenneth A.
    FASEB JOURNAL, 2019, 33
  • [24] Comparison of High Fidelity CRISPR Systems Using Cas9 Nickase Variants
    Chen, Fuqiang
    Kang, Qiaohua
    Huang, Yuping
    Davis, Gregory D.
    MOLECULAR THERAPY, 2014, 22 : S219 - S219
  • [25] An optimized SpCas9 high-fidelity variant for direct protein delivery
    Pedrazzoli, Eleonora
    Bianchi, Andrea
    Umbach, Alessandro
    Amistadi, Simone
    Brusson, Megane
    Frati, Giacomo
    Ciciani, Matteo
    Badowska, Kalina Aleksandra
    Arosio, Daniele
    Miccio, Annarita
    Cereseto, Anna
    Casini, Antonio
    MOLECULAR THERAPY, 2023, 31 (07) : 2257 - 2265
  • [26] Implementing accelerated dynamics to unravel the effects of high-fidelity Cas9 mutants on target DNA and guide RNA hybrid stability
    Vora, Dhvani Sandip
    Jaiswal, Atul Kumar
    Sundar, Durai
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2023, 41 (13): : 6178 - 6190
  • [27] COVID-19 Variant Detection with a High-Fidelity CRISPR-Cas12 Enzyme
    Fasching, Clare L.
    Servellita, Venice
    McKay, Bridget
    Nagesh, Vaishnavi
    Broughton, James P.
    Sotomayor-Gonzalez, Alicia
    Wang, Baolin
    Brazer, Noah
    Reyes, Kevin
    Streithorst, Jessica
    Deraney, Rachel N.
    Stanfield, Emma
    Hendriks, Carley G.
    Fung, Becky
    Miller, Steve
    Ching, Jesus
    Chen, Janice S.
    Chiu, Charles Y.
    JOURNAL OF CLINICAL MICROBIOLOGY, 2022, 60 (07)
  • [28] High Fidelity Genome Editing with a Novel Mutant HIF1 Cas9
    Vakulskas, Chris
    Collingwood, Michael
    Behlke, Mark
    MOLECULAR THERAPY, 2018, 26 (05) : 92 - 92
  • [29] A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells
    Vakulskas, Christopher A.
    Dever, Daniel P.
    Rettig, Garrett R.
    Turk, Rolf
    Jacobi, Ashley M.
    Collingwood, Michael A.
    Bode, Nicole M.
    McNeill, Matthew S.
    Yan, Shuqi
    Camarena, Joab
    Lee, Ciaran M.
    Parka, So Hyun
    Wiebking, Volker
    Bak, Rasmus O.
    Gomez-Ospina, Natalia
    Pavel-Dinu, Mara
    Sun, Wenchao
    Bao, Gang
    Porteus, Matthew H.
    Behlke, Mark A.
    NATURE MEDICINE, 2018, 24 (08) : 1216 - +
  • [30] A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells
    Christopher A. Vakulskas
    Daniel P. Dever
    Garrett R. Rettig
    Rolf Turk
    Ashley M. Jacobi
    Michael A. Collingwood
    Nicole M. Bode
    Matthew S. McNeill
    Shuqi Yan
    Joab Camarena
    Ciaran M. Lee
    So Hyun Park
    Volker Wiebking
    Rasmus O. Bak
    Natalia Gomez-Ospina
    Mara Pavel-Dinu
    Wenchao Sun
    Gang Bao
    Matthew H. Porteus
    Mark A. Behlke
    Nature Medicine, 2018, 24 : 1216 - 1224